Diagnostic Accuracy and Prognostic Value of Serial Prostate Multiparametric Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer
- PMID: 33483265
- DOI: 10.1016/j.euo.2020.11.007
Diagnostic Accuracy and Prognostic Value of Serial Prostate Multiparametric Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer
Abstract
Background: Multiparametric magnetic resonance imaging (MRI) is increasingly utilized to improve the detection of clinically significant prostate cancer. Evidence for serial MRI in men on active surveillance (AS) is lacking.
Objective: To evaluate the role of MRI in detecting Gleason grade group (GG) ≥2 disease in confirmatory and subsequent surveillance biopsies for men on AS.
Design, setting, and participants: This was a single-center study of men with low-risk prostate cancer enrolled in an AS cohort between 2006 and 2018. All men were diagnosed by systematic biopsy and underwent MRI prior to confirmatory ("MRI1") and subsequent surveillance ("MRI2") biopsies. MRI lesions were scored with Prostate Imaging Reporting and Data System (PI-RADS) version 2.
Outcome measurements and statistical analysis: The primary outcome was biopsy upgrade to GG ≥ 2 prostate cancer, and the secondary outcome was definitive treatment. Test characteristics for PI-RADS score were calculated. Multivariable logistic and Cox proportional hazard regression models were used to determine the associations between PI-RADS score change and outcomes, on a per-examination basis.
Results and limitations: Of 125 men with a median follow-up of 78 mo, 38% experienced an increase in PI-RADS scores. The sensitivity and positive predictive value of PI-RADS ≥3 for GG ≥ 2 disease improved from MRI1 to MRI2 (from 85% to 91% and from 26% to 49%, respectively). An increase in PI-RADS scores from MRI1 to MRI2 was associated with GG ≥ 2 (odds ratio [OR] 4.8, 95% confidence interval [CI] 1.7-13.2) compared with PI-RADS 1-3 on both MRI scans. Men with PI-RADS 4-5 lesions on both MRI scans had a higher likelihood of GG ≥ 2 than patients with PI-RADS 1-3 lesions on both (OR 3.3, 95% CI 1.3-8.6). Importantly, any increase in PI-RADS scores was independently associated with definitive treatment (hazard ratio 3.9, 95% CI 1.3-11.9). This study was limited by its retrospective, single-center design.
Conclusions: The prognostic value of MRI improves with serial examination and provides additional risk stratification. Validation in other cohorts is needed.
Patient summary: We looked at the role of serial prostate magnetic resonance imaging in men with low-risk prostate cancer on active surveillance at the University of California, San Francisco. We found that both consistently visible and increasingly suspicious lesions were associated with biopsy upgrade and definitive treatment.
Keywords: Active surveillance; Confirmatory biopsy; Multiparametric magnetic resonance imaging; Outcome research; Prostate cancer; Surveillance biopsy.
Copyright © 2020 European Association of Urology. Published by Elsevier B.V. All rights reserved.
Similar articles
-
Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.BJU Int. 2017 Oct;120(4):511-519. doi: 10.1111/bju.13836. Epub 2017 Apr 4. BJU Int. 2017. PMID: 28267899
-
Outcomes of Serial Multiparametric Magnetic Resonance Imaging and Subsequent Biopsy in Men with Low-risk Prostate Cancer Managed with Active Surveillance.Eur Urol Focus. 2021 Jan;7(1):47-54. doi: 10.1016/j.euf.2019.05.011. Epub 2019 May 27. Eur Urol Focus. 2021. PMID: 31147263
-
Genomic Prostate Score, PI-RADS™ version 2 and Progression in Men with Prostate Cancer on Active Surveillance.J Urol. 2019 Feb;201(2):300-307. doi: 10.1016/j.juro.2018.08.047. J Urol. 2019. PMID: 30179620
-
Positive Predictive Value of Prostate Imaging Reporting and Data System Version 2 for the Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysis.Eur Urol Oncol. 2021 Oct;4(5):697-713. doi: 10.1016/j.euo.2020.12.004. Epub 2020 Dec 25. Eur Urol Oncol. 2021. PMID: 33358543
-
Practice-Level Variation in the Decision to Biopsy Prostate Imaging-Reporting and Data System 3 Lesions in Favorable-Risk Prostate Cancer Patients.Urology. 2022 Jun;164:191-196. doi: 10.1016/j.urology.2022.01.020. Epub 2022 Jan 23. Urology. 2022. PMID: 35081398 Review.
Cited by
-
The presence of prostate MRI-visible lesions at follow-up biopsy as a risk factor for histopathological upgrading during active surveillance.Abdom Radiol (NY). 2025 Sep;50(9):4311-4319. doi: 10.1007/s00261-025-04871-6. Epub 2025 Mar 12. Abdom Radiol (NY). 2025. PMID: 40072539
-
Prospective evaluation of the role of imaging techniques and TMPRSS2:ERG mutation for the diagnosis of clinically significant prostate cancer.Front Oncol. 2022 Sep 6;12:968384. doi: 10.3389/fonc.2022.968384. eCollection 2022. Front Oncol. 2022. PMID: 36147926 Free PMC article.
-
Integrating shear wave elastography and multiparametric MRI for accurate prostate cancer diagnosis.Am J Cancer Res. 2025 Jan 15;15(1):348-362. doi: 10.62347/SNMS7524. eCollection 2025. Am J Cancer Res. 2025. PMID: 39949940 Free PMC article.
-
Outcomes and predictors of clinically significant prostate cancer detection by transperineal computer fusion biopsy during active surveillance.Cent European J Urol. 2024;77(3):418-423. doi: 10.5173/ceju.2024.95.R1. Epub 2024 Oct 29. Cent European J Urol. 2024. PMID: 40115486 Free PMC article.
-
Evaluating 4Kscore's role in predicting progression on active surveillance for prostate cancer independently of clinical information and PIRADS score.Prostate Cancer Prostatic Dis. 2025 Mar;28(1):180-186. doi: 10.1038/s41391-024-00898-w. Epub 2024 Sep 27. Prostate Cancer Prostatic Dis. 2025. PMID: 39333697
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous